Explore

Rapid Read Rapid Read
Mayo Clinic and Virginia Tech Identify Five Subgroups of Non-Alcoholic Fatty Liver Disease

Mayo Clinic and Virginia Tech Identify Five Subgroups of Non-Alcoholic Fatty Liver Disease

A collaborative study by the Mayo Clinic and Virginia Tech, published in Nature Communications, has identified five distinct subgroups of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease. Researchers analyzed clinical histories and genetic data from over 4,600 patients to uncover patterns that were previously obscured when MASLD was treated as a single condition. The study categorized these subgroups, labeled C1 through C5, each exhibiting different clinical characteristics and risks. For instance, C2 predominantly featured men with a cardiorenal profile, while C3 was more common in women and linked to obesity and mood disorders. Notably, C4, despite having fewer metabolic comorbidities, showed the highest rate of liver transplants, attributed to an unfavorable combination of genetic variants. C5, characterized as polygenic MASLD/MASH, presented a higher risk of advanced fibrosis and acute renal failure. This research suggests that MASLD ...
Rapid Read Rapid Read
Harvard Medical School Researchers Unlock Insulin Production in Pancreatic Cells by Disabling Gene

Harvard Medical School Researchers Unlock Insulin Production in Pancreatic Cells by Disabling Gene

Researchers at Harvard Medical School have discovered a method to transform a patient's own pancreatic cells into insulin-producing cells by disabling a specific gene. The study, published in Science Translational Medicine, identified the ALDH3B2 gene as a molecular 'brake' that prevents pancreatic duct cells from changing their identity. By using advanced CRISPR gene-editing technology to silence ALDH3B2, the researchers were able to induce human pancreatic duct cells to convert into beta-like cells, which are responsible for insulin production. Under natural conditions, less than 1% of duct cells transform into beta cells, but disabling ALDH3B2 increased this rate to approximately 8.5% in human cells. These reprogrammed human cells, when transplanted into diabetic, immune-deficient mice, successfully lowered blood sugar to near-normal levels for six weeks.
Rapid Read Rapid Read
ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen, the Clinical Genome Resource, and the Clinical Pharmacogenomics Resource (ClinPGx), which includes the Clinical Pharmacogenetics Implementation Consortium (CPIC), have formed a critical partnership. This collaboration aims to expand ClinGen’s extensive clinical genetics resources to incorporate pharmacogenomics (PGx) knowledge. ClinPGx serves as a primary resource for the PGx research and implementation communities, offering expert-curated gene-drug and variant-drug summaries based on peer-reviewed publications, clinical guidelines, and regulatory drug labels. The partnership facilitates the characterization and dissemination of the clinical relevance of pharmacogenetic variations through transparent and documented Standard Operating Procedures (SOPs). While ClinGen’s Expert Panels focus on gene-disease relationships, ClinPGx specializes in gene-drug and variant-drug associations, providing a comprehensive view of how genetic variations influence drug responses. This integration ensures that pharm...
Rapid Read Rapid Read
UK Halts Large Military Exercises Due to Funding Shortfalls, Redirecting Focus to Drone Transformation

UK Halts Large Military Exercises Due to Funding Shortfalls, Redirecting Focus to Drone Transformation

The British Armed Forces have suspended military exercises involving 90 or more personnel due to budget constraints within the Ministry of Defense. Units have been instructed to cease collective training immediately, unless they are preparing for active deployment. This directive significantly reduces company-level and battle group training, impacting major events such as a six-week exercise with tanks and attack helicopters in Wales. While small squad training for basic skills like vehicle operation, physical fitness, weapons handling, and drone usage will continue, the Royal Navy and Royal Air Force are also scaling back training activities. The cuts are attributed to a shortage of funds for current operating expenses, with an allocated £2 billion for training not becoming available until 2027. This financial imbalance is partly due to costly rearmament programs, including nuclear submarines and a sixth-generation fighter jet. The Ministry of Defense is now prioritizing a strategy focused on low-cost sys...
Trendline Trendline
Halliburton Contracted by Cornish Lithium for Geothermal Lithium Extraction Project in UK

Halliburton Contracted by Cornish Lithium for Geothermal Lithium Extraction Project in UK

Halliburton Contracted by Cornish Lithium for Geothermal Lithium Extraction Project in UK
Trendline Trendline
Indoor Light Therapy Improves Sleep and Activity Levels in Older Adults

Indoor Light Therapy Improves Sleep and Activity Levels in Older Adults

Indoor Light Therapy Improves Sleep and Activity Levels in Older Adults
Rapid Read Rapid Read
FDA Approves Novel Cellular Therapies and Expanded Indications for Solid Tumors, Advancing Precision Oncology

FDA Approves Novel Cellular Therapies and Expanded Indications for Solid Tumors, Advancing Precision Oncology

The U.S. Food and Drug Administration (FDA) has recently granted expanded indications and approved a novel cellular therapy for the treatment of solid tumors. This development significantly impacts oncology by enabling customized medicines based on individual patients' specific genetic mutations, bioprocesses, or immune system characteristics. Among the new approvals, Amtagvi (lifileucel) stands out as the first and only cellular therapy to receive FDA approval for a solid tumor cancer, specifically for unresectable advanced melanoma. Additionally, Enhertu (fam-trastuzumab deruxtecan, T-Dxd) received accelerated approval for adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and lack satisfactory alternative options. These approvals underscore a growing trend in precision medicine, where treatments are tailored to a patient's unique cancer characteristics, moving away from one-size-fits-all approaches. The pipeline for oncology drugs heavily...
Rapid Read Rapid Read
NYU Langone Health Study Links GLP-1 Drugs to Increased Hair Loss Risk in Genetically Predisposed Men

NYU Langone Health Study Links GLP-1 Drugs to Increased Hair Loss Risk in Genetically Predisposed Men

A new study led by researchers at NYU Langone Health indicates that men with a genetic predisposition for androgenetic alopecia, the most common form of hair loss, face an additional 7% risk of hair loss when using GLP-1 medications such as Ozempic, Wegovy, and Zepbound. These drugs are prescribed for type 2 diabetes and obesity. The study, published online on September 3 in the Journal of Investigative Dermatology, focused on the GLP1R gene, which is associated with increased levels of glucagon-like peptide-1 (GLP-1) receptor proteins. Researchers compared the presence of GLP1R genes with genes found in men with androgenetic alopecia, an inherited pattern baldness. While rapid weight loss has previously been cited as a cause for hair thinning among GLP-1 users, this study provides the first genetic link, suggesting a biological connection. The analysis accounted for other known risk factors for hair loss, including hypertension, insulin resistance, and lowered testosterone levels, yet the 7% increased ris...
Trendline Trendline
Menarini Group Secures European Rights for Bofanglutide, a GLP-1 Therapeutic, from Gan Lee Pharmaceuticals

Menarini Group Secures European Rights for Bofanglutide, a GLP-1 Therapeutic, from Gan Lee Pharmaceuticals

Menarini Group Secures European Rights for Bofanglutide, a GLP-1 Therapeutic, from Gan Lee Pharmaceuticals
Trendline Trendline
Hachette Book Group and Hachette UK Launch Joint 'Raising Readers' Campaign with U.S. and U.K. Storytimes

Hachette Book Group and Hachette UK Launch Joint 'Raising Readers' Campaign with U.S. and U.K. Storytimes

Hachette Book Group and Hachette UK Launch Joint 'Raising Readers' Campaign with U.S. and U.K. Storytimes
Rapid Read Rapid Read
URI Students and Faculty Utilize Continuous Glucose Monitors to Support Children with Type 1 Diabetes at Summer Camp

URI Students and Faculty Utilize Continuous Glucose Monitors to Support Children with Type 1 Diabetes at Summer Camp

The University of Rhode Island (URI) is actively involved in Camp Surefire, a sleepaway summer camp for children aged 7 to 17 with Type 1 diabetes, located at Camp JORI in South Kingstown. URI health sciences, pharmacy, and nursing students, along with faculty, provide 24-hour medical supervision, ensuring campers' blood sugar levels are continuously monitored and managed. Campers use Continuous Glucose Monitors (CGMs) and report their levels via a phone app, which digitally transmits the data to a large video board for real-time monitoring by medical staff. This system allows children with Type 1 diabetes to experience traditional summer camp activities like swimming and kayaking while their health is closely tracked. The medical team, including URI student nurses and pharmacists, is trained to operate CGMs, insulin pumps, and glucometers, and to respond to blood sugar fluctuations. Robyn Perry, lead dietitian for the camp and a URI clinical instructor, emphasizes the delicate balance of managing insulin ...
Trendline Trendline
U.S. Ports and Maersk Partner to Explore Transatlantic Nuclear Shipping Corridor

U.S. Ports and Maersk Partner to Explore Transatlantic Nuclear Shipping Corridor

U.S. Ports and Maersk Partner to Explore Transatlantic Nuclear Shipping Corridor